Imugene (ASX:IMU) will raise AU$46 million via the issue of notes and warrants to investor CVI Investments, according to a Monday filing with the Australian bourse.
The offer comprises AU$20 million in senior unsecured zero-coupon convertible notes maturing in five years and AU$26 million worth of five-year unlisted warrants exercisable at AU$0.0494, the filing said.
If the investor decides to convert the bonds into shares, its conversion value will be 25% above the immuno-oncology firm's closing price on Dec. 20, per the filing.
Proceeds will be used to advance the company's azer-cel, onCARlytics, and Vaxinia trials, as per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。